CAH vs MCK
Cardinal Health and McKesson Corporation, both Healthcare
McKesson Corporation is the larger company at $111B against $55B. Over the past year CAH returned +60% against +37% for MCK. The RyuScore puts MCK ahead, 86 against 61 out of 100.
| Figure | CAH | MCK |
|---|---|---|
| Last close | $238 | $955 |
| Market cap | $55B | $111B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 25.6 |
| Dividend yield | 0.9% | n/a |
| 1-year return | +60% | +37% |
| 5-year return | +408% | +380% |
| RyuScoresector-relative, 1–10 | 61/100 | 86/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Cardinal Health
Revenue of $125B in H2 2026, net income $797M. Its largest reported line is Pharmaceutical And Specialty Solutions, 94% of the disclosed total.
McKesson Corporation
Revenue of $105B in Q1 2027, net income $614M. Its largest reported line is North American Pharmaceutical, 82% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.